香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 截至二零二四年十二月三十一日止年度之 經審核業績公告 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （統稱「本集團」）截至二零二四年十二月三十一日止年度之經審核綜合業績如下： 綜合損益及其他全面收益表 截至二零二四年十二月三十一日止年度 | | | 二零二四年 | 二零二三年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 收入 | 3 | 897,521 | 809,107 | | 銷售及服務成本 | | (381,364) | (337,815) | | 毛利 | | 516,157 | 471,292 | | 其他收入 | 4 | 34,362 | 24,469 | | 其他收益及虧損 | | (26,532) | 111,162 | | 預期信貸虧損模式項下之減值虧損，扣除撥回金額 | | (49, ...

www.a星级 SHANXIC IG 華控康泰集團有限公司 Kontafarma China Holdings Limited （於開曼群島柱冊成立之有限公司）(Incorporated in the Cayman Islands with limited liability) (股份代號 Stock Code: 1312) 2024 中期業績報告 INTERIM REPORT American Property 0 目錄 Contents 公司資料 Corporate Information 2 簡明綜合損益及其他全面收益表 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 5 簡明綜合財務狀況表 Condensed Consolidated Statement of Financial Position 7 簡明綜合權益變動表 Condensed Consolidated Statement of Changes in Equity 9 簡明綜合現金流動表 Condensed Consolid ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 ( 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ) （股份代號：1312） 截至二零二四年六月三十日止六個月之 未經審核中期業績 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （「本集團」）截至二零二四年六月三十日止六個月之未經審核簡明綜合中期業績連同二零 二三年同期之比較數字如下。本集團截至二零二四年六月三十日止六個月之中期財務業 績乃未經審核，但已由本公司審核委員會（「審核委員會」）及本公司核數師香港立信德豪 會計師事務所有限公司作出審閱。 簡明綜合損益及其他全面收益表 截至二零二四年六月三十日止六個月 | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------- ...

(股份代號 Stock Code: 1312) （於開曼群島註冊成立之有限公司） (Incorporated in the Cayman Islands with limited liability) ANNUAL REPORT 2023 年報 C004888 ANNUAL REPORT 2023 年報 目錄 CONTENTS 公司資料 Corporate Information 2 5 主席報告 Chairman's Statement 8 管理層討論及分析 Management Discussion and Analysis 19 環境、社會及管治報告 Environmental, Social and Governance Report 73 企業管治報告 Corporate Governance Report 100 董事會報告 Directors' Report 124 獨立核數師報告 Independent Auditor's Report 133 綜合損益及其他全面收益表 Consolidated Statement of Profit or Loss and Other Comprehensi ...

智通财经APP讯，华控康泰(01312)发布公告，黄俞先生(黄先生)因其他工作承担已由公司执行董事调任为非执行董事，自2024年4月19日起生效。彼将同时不再担任集团行政总裁以及董事会执行委员会及董事会股份交易委员会各自的成员。 于2024年4月16日，公司收到深圳市华融泰资产管理有限公司(深圳市华融泰)的函件(提议通知)，要求根据组织章程细则尽快召开及举行公司特别股东大会，以供考虑及酌情通过决议案，以委任王飞飞先生、乔琳娜女士、郭姿秀女士及刘剑焜先生为执行董事;及委任邓丽华博士、何昊洺博士及姚小民先生为独立非执行董事，于有关普通决议案获通过后即时生效(如获通过)。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 截至二零二三年十二月三十一日止年度之 經審核業績公告 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （統稱「本集團」）截至二零二三年十二月三十一日止年度之經審核綜合業績如下： 綜合損益及其他全面收益表 截至二零二三年十二月三十一日止年度 | | | 二零二三年 | 二零二二年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 持續經營業務 | | | | | 收入 | 3 | 809,107 | 894,062 | | 銷售及服務成本 | | (337,815) | (387,841) | | 毛利 | | 471,292 | 506,221 | | 其他收入 | 4 | 24,469 | 37,928 | | 其他收益及虧損 | | 111,162 | 4,907 | | 預期信貸虧損模式項下之減值虧損， ...

(股份代號 Stock Code: 1312) （於開曼群島註冊成立之有限公司） (Incorporated in the Cayman Islands with limited liability) 2023 INTERIM REPORT 中期業績報告 目錄 Contents | 公司資料 | Corporate Information | 2 | | --- | --- | --- | | 簡明綜合損益及其他全面收益表 | Condensed Consolidated Statement of | 5 | | | Profit or Loss and Other Comprehensive Income | | | 簡明綜合財務狀況表 | Condensed Consolidated Statement of | 7 | | | Financial Position | | | 簡明綜合權益變動表 | Condensed Consolidated Statement of | 9 | | | Changes in Equity | | | 簡明綜合現金流動表 | Condensed Consolidate ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 截至二零二三年六月三十日止六個月之 未經審核中期業績 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （「本集團」）截至二零二三年六月三十日止六個月之未經審核簡明綜合中期業績連同二零 二二年同期之比較數字如下。本集團截至二零二三年六月三十日止六個月之中期財務業 績乃未經審核，但已由本公司審核委員會（「審核委員會」）及本公司核數師香港立信德豪 會計師事務所有限公司作出審閱。 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 截至六月三十日止六個月 二零二三年 二零二二年 附註 千港元 千港元 （未經審核） （未經審核） 持續經營業務 收入 5 430,705 451,085 銷售及服務成本 (183,427) (183,610) ...

Financial Performance - The Group's revenue for the year ended December 31, 2022, was approximately HK$894.1 million, an increase of approximately 11.3% compared to HK$803.3 million in 2021[14][18]. - The Group reported a loss of approximately HK$52.8 million for the year, compared to a loss of approximately HK$4.6 million in 2021[14][18]. - Basic loss per share amounted to approximately HK$0.74 cent, compared to approximately HK$0.27 cent in the previous year[18]. - The net loss for the year ended December 31, 2022, was approximately HK$109.7 million, an increase of approximately HK$53.4 million compared to the net loss of HK$56.3 million in 2021[44]. - Basic loss per share for 2022 was approximately HK$1.52 cents, compared to HK$0.86 cents in 2021[44]. - The increase in net loss was attributed to higher distribution and selling expenses due to market expansion in the pharmaceutical segment[46]. - The fitness business of the Group generated revenue of approximately HK$171.2 million in 2022, an increase of approximately 6.1% from HK$161.3 million in 2021[74]. - The net loss for the Group's fitness business widened to approximately HK$46.0 million in 2022, compared to HK$26.4 million in 2021[74]. Dividend Policy - The Board has resolved not to recommend any final dividend for the year ended December 31, 2022[19]. - The Company adopted a dividend policy in December 2018, aiming for stable and sustainable returns to shareholders[20]. Business Segments - The Group focuses on human health and aims to create value for all stakeholders through quality services[24]. - The pharmaceutical business segment did not experience supply chain disruptions in 2022, which positively impacted sales, unlike in 2021 when a major supplier failed to deliver on time[41]. - The fitness business segment showed gradual improvement as it overcame the impacts of the COVID-19 pandemic[44]. - Government grants and subsidies related to the COVID-19 pandemic decreased compared to the previous year, impacting the fitness business segment[46]. - The Group plans to focus on the development of its existing advantageous chemical generic medicine and active pharmaceutical ingredients industries[29]. - The Group aims to extend its business reach to emerging sub-sectors to provide better long-term returns to shareholders[29]. Employee and Operational Metrics - The Group had 922 employees as of December 31, 2022, a decrease of 29.4% from 1,305 employees in 2021[99]. - As of December 31, 2022, the Group maintained bank balances and cash reserves of approximately HK$122.6 million, down from approximately HK$174.2 million in 2021[84]. - The Group's outstanding borrowings repayable within one year were approximately HK$158.8 million as of December 31, 2022, compared to approximately HK$226.7 million in 2021[85]. - The gearing ratio of the Group as of December 31, 2022, was 12.4%, up from 9.5% in 2021[87]. Environmental, Social, and Governance (ESG) Initiatives - The Group's environmental, social, and governance report outlines its commitment to sustainable operations and stakeholder interests[108]. - The Group is committed to operating sustainably, balancing stakeholder interests while positively impacting society[112]. - The ESG Report is prepared based on principles of materiality, quantitative data, balance, and consistency[113]. - The Board oversees the effective implementation of ESG policies, including risk management and performance review[120]. - The Executive Committee and management are responsible for formulating policies and allocating budgets for ESG activities[134]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[134]. - A robust ESG governance structure has been established, consisting of the Board, Executive Committee, management, and working groups[121]. - The Group integrates data from functional departments and subsidiaries to assess ESG performance[135]. - Regular assessments of ESG-related progress and performance are conducted, with reports submitted to the Board[128]. - The Group's strategy focuses on promoting sustainable economies and enhancing value for business partners and shareholders[134]. Waste and Emissions Management - The company aims to reduce gas emissions by regularly conducting exhaust gas monitoring to meet government emission standards, including the Emission Standard of Air Pollutants for Catering Industry and others[162]. - The company has reduced indirect CO2 emissions from electricity consumption to approximately 2,110 tons in 2022, down from 4,034 tons in 2021, with a per capita CO2 density of 3.25 tons[169]. - The company has eliminated heavily-polluted production lines and replaced facilities to reduce emissions, including installing electrostatic fume purifiers and low-nitrogen burners[166]. - The company has upgraded its wastewater treatment system to a three-stage process to further reduce emissions of harmful gases like formaldehyde[168]. - The company has implemented energy-saving actions and purchased new exhaust treatment equipment to enhance emission reduction efforts[168]. - The company has focused on monitoring and controlling the concentration of exhaust gas emissions to ensure compliance with pollutant discharge permits[166]. - The Group has implemented waste sorting and hazardous waste management, signing disposal agreements to enhance treatment efficiency and reduce environmental risks[189]. - The Fitness Business reported no significant emissions of hazardous and non-hazardous wastes in 2022[189]. Renewable Energy Initiatives - A solar energy power generation project has been implemented in the Beijing plant, covering over 30,000 square feet, fulfilling daily energy consumption needs, and selling surplus energy to nearby plants[165]. - The company generated approximately 2,490,000 kWh of clean energy from solar power in 2022, a decrease from approximately 3,910,000 kWh in 2021[198]. - The total electricity consumption for the year 2022 was 6.99 million kWh, down from 13.36 million kWh in 2021, with a per capita electricity consumption density of 0.0108 million kWh[200]. - The company has implemented energy-saving measures, including phasing out high-energy-consuming refrigeration equipment, which has improved production efficiency[200]. Challenges and Market Conditions - Shaanxi Unisplendour faced challenges due to rising raw material prices and the lingering effects of the COVID-19 pandemic[65]. - Chongqing Kangle experienced negative impacts from rising raw material prices and extreme weather conditions in 2022[69]. - The overall operation of Tongfang Pharmaceutical returned to normal levels in 2022, aided by the absence of major product supplier delivery failures[58].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任 何損失承擔任何責任。 截至二零二二年十二月三十一日止年度之 經審核業績公告 華控康泰集團有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈本公司及其附屬公司 （統稱「本集團」）截至二零二二年十二月三十一日止年度之經審核綜合業績如下： 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 （經重列） 持續經營業務 收入 3 894,062 803,267 銷售及服務成本 (387,841) (407,091) 毛利 506,221 396,176 其他收入 4 37,928 74,596 其他收益及虧損 4,907 24,456 預期信貸虧損模式項下之減值虧損， ...